uploads///Analysts Ratings

What Analysts Recommend for United Therapeutics in November 2017

By

Dec. 4 2017, Updated 9:03 a.m. ET

Recent developments

In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018. United Therapeutics commercializes Adcira in the US as per its license agreement with Eli Lilly. The US patent for Adcirca expired on November 21, 2017, but the FDA’s regulatory approval for market exclusivity will help United Therapeutics commercialize exclusively for another six months. The extension of market exclusivity of Adcirca is expected to continue to boost the revenue growth of United Therapeutics during the rest of 2017 and 1H18.

Article continues below advertisement

Analyst recommendations

13 analysts were tracking United Therapeutics in November 2017. Two of them recommended a “strong buy.” Six analysts recommended a “hold,” while four analysts recommended a “sell,” and one analyst recommended a “strong sell.”

On November 29, 2017, United Therapeutics had a consensus 12-month target price of $123.83, which represents a ~0.6% decline over the next 12 months. Notably, the iShares Nasdaq Biotechnology ETF (IBB) invests ~0.79% of its total portfolio holdings in United Therapeutics.

Competitor ratings

Of the 21 analysts tracking Incyte (INCY) in November 2017, five recommended a “strong buy,” while 12 analysts recommended a “buy.” Four of them recommended a “hold.” On November 29, 2017, Incyte had a consensus 12-month target price of $148.63, a 55.1% upside for the next 12 months.

Of the 18 analysts tracking Alnylam Pharmaceuticals (ALNY) in November 2017, two of them recommended a “strong buy,” while 11 analysts recommended a “buy.” Four analysts recommended a “hold,” while one of them recommended a “sell.”

On November 29, 2017, Alnylam Pharmaceuticals had a mean 12-month target price of $145.33, which represents a 12% return on investment over the next 12 months.

Of the 16 analysts tracking Seattle Genetics (SGEN) in November 2017, three analysts suggested a “strong buy,” while five analysts suggested a “buy.” Eight analysts recommended a “hold.”

On November 29, 2017, Seattle Genetics had a mean 12-month target price of $64.57, which represents ~10% return on investment over the next 12 months.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.